ETD Collection

Permanent URI for this collectionhttps://wiredspace.wits.ac.za/handle/10539/104


Please note: Digitised content is made available at the best possible quality range, taking into consideration file size and the condition of the original item. These restrictions may sometimes affect the quality of the final published item. For queries regarding content of ETD collection please contact IR specialists by email : IR specialists or Tel : 011 717 4652 / 1954

Follow the link below for important information about Electronic Theses and Dissertations (ETD)

Library Guide about ETD

Browse

Filters

2013 - 20162

Settings

Author: search.filters.author.Moodley, Kiashanee

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Characterization of the fibroblast growth factor receptor 2 splicing mechanism in triple-negative breast cancer
    (2016-10-28) Moodley, Kiashanee
    Breast cancer is the second most frequently diagnosed cancer in the world and the most frequently diagnosed cancer in women. Triple-negative breast cancer (TNBC), a subtype of breast cancer, is characterised by the lack of expression of the oestrogen receptor, progesterone receptor and a lack of overexpression of the human epidermal growth factor receptor 2. Therapeutic options targeting TNBCs are limited, and since it can be more aggressive compared to other breast cancer subtypes, research into its progression is necessary. A number of genome-wide association studies have identified an association between the fibroblast growth factor receptor (FGFR) 2 and the risk of breast cancer. This receptor is alternatively spliced, and a switch in the mutually exclusive inclusion of either the FGFR2 IIIb or the FGFR2 IIIc exons is associated with epithelial-to-mesenchymal transition (EMT) and mesenchymal-to-epithelial transition (MET). A nuclear proteomic analysis comparing an epithelial TNBC cell line to a mesenchymal one revealed that the RNA binding protein, KH-type Splicing Regulatory Protein (KSRP), is overexpressed in the basal cell line compared to the mesenchymal cell line; these cell lines preferentially include FGFR2 IIIb and FGFR2 IIIc, respectively. This project aimed to investigate the role of KSRP in the FGFR2 splicing mechanism in the context of triple-negative breast cancer progression using epithelial and mesenchymal cell line models. In addition, this project aimed to discover the genome-wide consequences of KSRP knockdown. The epithelial and mesenchymal phenotypes, preferential FGFR2 isoform inclusion, differential expression of KSRP and alteration of FGFR2 isoform expression in MDA-MB-468 (epithelial) and MDA-MB-436 (mesenchymal) cells were confirmed using fluorescent microscopy, semi-quantitative polymerase chain reaction, quantitative real-time PCR (qRT-PCR), and western blotting. qRT-PCR was used to determine whether the expression of FGFR2 IIIb and FGFR2 IIIc became altered in response to changes in the expression of KSRP (either upor downregulation). Fluorescent microscopy was used to determine if changes in the phenotypes of the epithelial and mesenchymal cells were the consequence of the KSRP mediated changes in FGFR2 IIIb and FGFR2 IIIc expression. The ultraviolet cross-linking and immunoprecipitation (UV-CLIP) technique was used to investigate whether KSRP binds directly to FGFR2 mRNA in epithelial cells. We report that the role of KSRP in FGFR2 splicing involves the tissue-specific control of the expression of FGFR2 IIIb and FGFR2 IIIc. KSRP up- and downregulation in MDA-MB-436 causes an upregulation of FGFR2 IIIb and FGFR2 IIIc expression. KSRP up- and downregulation in MDA-MB-468 cells causes a downregulation of FGFR2 IIIb and FGFR2 IIIc expression. The efficiency of the upregulation (in MDA-MB-436 cells) and downregulation (in MDA-MB-468 cells) in FGFR2 IIIb expression is different to that of FGFR2 IIIc expression, this is dependent on the level of KSRP expression. A clear switch from the splicing of FGFR2 IIIb to FGFR2 IIIc, or vice versa, in response to manipulation of KSRP expression, was not observed in epithelial and mesenchymal cells, indicating that this protein does not control the mutually exclusive splicing nature of this gene. We also show that KSRP does not control EMT or MET in epithelial or mesenchymal cells and that KSRP directly binds to FGFR2 mRNA at exon 9 (FGFR2 IIIb) in epithelial cells. This role of KSRP in FGFR2 isoform inclusion and the direct binding of KSRP to FGFR2 mRNA have not been previously reported. The Affymetrix GeneChip® Human Transcriptome Array 2.0 was used to identify the genome-wide consequences of KSRP knockdown in epithelial cells. Numerous significant changes in gene expression in response to KSRP knockdown were observed. In particular, three genes involved in the canonical Wnt pathway – namely Cyclin D3 (CCND3), Dickkopf WNT Signaling Pathway Inhibitor 1 (DKK1) and Protein Phosphatase 2, Regulatory Subunit A, Beta (PPP2R1B) – were upregulated in response to KSRP downregulation, suggesting a regulatory role of KSRP in this pathway. CCND3, DKK1 and PPP2R1B were chosen for further analysis and the change in their expression in response to KSRP downregulation was validated using qRT-PCR. A possible direct interaction between KSRP and the selected targets was predicted using STRING and investigated using confocal fluorescence microscopy. KSRP was not predicted to interact with any of these proteins but interestingly co-localises with DKK1. This suggests that KSRP and DKK1 directly interact and that KSRP could antagonise Wnt signalling. This link between KSRP, DKK1 and the Wnt pathway has not been previously reported.
  • No Thumbnail Available
    Item
    The effect of the siRNA-mediated downregulation of the non-integrin laminin receptor on cancer cell viability
    (2013-08-08) Moodley, Kiashanee
    Cancer is a hypernym used to describe a group of diseases characterised by the uninhibited growth and spread of abnormal cells in the body. An estimated 7.6 million annual deaths are attributed to the disease while 12.7 million new cases are reported every year. The severity of this disease demonstrates the urgent requirement of novel anti-cancer therapeutic agents. The non-integrin laminin receptor, here designated the 37 kDa/67 kDa laminin receptor (LRP/LR), is a multifunctional protein located on the surface, in the cytoplasm, in the perinuclear compartment and in the nucleus of cells. While this receptor is imperative for normal cellular functioning, it has also been implicated in many diseases – it serves as a cell surface receptor for numerous viruses, infectious prion proteins as well as certain respiratory tract pathogens. Additionally, LRP/LR has been found to have some involvement in zoonotic diseases and those involving neurodegeneration, such as Alzheimer’s disease. Most importantly for this study, LRP/LR has been implicated in cancer progression, where it was found to be overexpressed on the surface of various cancer cell lines, this overexpression correlating to increased metastasis. The aim of this study was to investigate the effect of the siRNA-mediated downregulation of LRP expression on the viability of tumorigenic lung and cervical cancer cells (A549 and HeLa, respectively). The cell surface LRP/LR and total LRP levels were investigated using flow cytometry and western blotting, respectively, in A549 and HeLa cells, the results revealing high percentages of both cell lines expressing LRP/LR on their surface. Additionally, A549 and HeLa cells express similar total levels LRP. The transfectability of these cells was confirmed and siRNA-LAMR1 was shown to significantly downregulate LRP expression (80% and 60% in A549 and HeLa cells, respectively). MTT assays revealed that the significant 13% and 18% reduction in cellular viability in A549 and HeLa cells, respectively, was as a consequence of LRP downregulation. This reduction in cellular viability was found to be a consequence of induced apoptosis (identified by the visualisation of the loss in nuclear integrity, as well as the significantly increased activity of the apoptosis-associated protein caspase- 3) and inhibited cellular proliferation in the aforementioned cells. These findings suggest that siRNA targeting LRP mRNA may act as a potential alternative therapeutic tool for the teatment of cancer.